iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Indian CROs should not assume that a foreign clinical-trial sponsor makes their services GST-free. First determine what the CRO supplies, who supplies and receives it, where the place of supply falls under the applicable rule—including the pharmaceutical R&D notification—and whether every statutory export condition is met. If the service qualifies as an export, it is zero-rated; if it does not, confirm the taxable classification and rate before fixing the quote. The answer depends on the contract and facts, not just the sponsor’s location.
Start with the contracted work, not the sponsor’s country
A CRO’s scope may include several responsibilities, deliverables and payment milestones. Describe what the Indian contracting entity actually undertakes, and identify any separately identifiable services or reimbursable items. A generic description such as “clinical research” may not capture the facts needed to assess classification or place of supply.
CDSCO describes a CRO as a body to which a sponsor may delegate or transfer, in writing, some or all tasks, duties or obligations relating to a clinical trial or bioavailability/bioequivalence study. CDSCO also says a valid clinical-trial agreement should be in place before trial-related activity begins. The agreement and statement of work therefore matter to the tax analysis as well as to trial governance.
How to decide whether a service qualifies as an export
Under section 2(6) of the Integrated Goods and Services Tax Act, “export of services” depends on a set of conditions. Check them against the actual transaction rather than treating foreign sponsorship or an offshore payment as conclusive.
#1 Best Overall
- Supplier: The supplier of the service must be located in India. Confirm which legal entity performs and invoices the work.
- Recipient: The recipient must be located outside India. Identify the entity that receives the service under the contract; distinguish it from a sponsor’s Indian affiliate or other contracting party.
- Place of supply: The place of supply must be outside India. This is a separate legal test, not an automatic consequence of the recipient being foreign.
- Payment: Consideration must be received in convertible foreign exchange or in Indian rupees where permitted by the Reserve Bank of India.
- Separate establishments: The supplier and recipient must not be merely establishments of the same person under the statutory distinct-person test.
These conditions work together. A foreign sponsor and a payment received from abroad do not, by themselves, establish export treatment.
Why the place-of-supply analysis needs special care
The cross-border default has exceptions
Section 13(2) generally places the supply of a service at the recipient’s location, but it is subject to exceptions in section 13 and notified rules. Section 13(3), for example, addresses services supplied in respect of goods made physically available to the supplier and services supplied to an individual who must be physically present with the supplier. The relevant question is how the statutory provisions apply to the CRO’s contracted service components and facts—not simply where staff perform the work.
Clinical trials fall within a notified pharmaceutical R&D framework
At its 37th meeting, the GST Council identified clinical trials among pharmaceutical-sector R&D services for which place-of-supply rules would be notified by reference to effective use and enjoyment. CBIC’s notification index identifies Notification 4/2019-Integrated Tax, dated 30 September 2019, as the section 13(13) notification on pharmaceutical-sector R&D services. Before treating a CRO service as an export or taxable supply, check the notification’s operative wording, conditions and application to the actual contracted components. A general reliance on the section 13(2) default is not enough.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
The Maharashtra Authority for Advance Ruling’s 4 May 2019 decision concerning Cliantha Research Limited addressed proposed clinical-research services for entities outside India. It is a fact-specific advance ruling, not a universal determination for all Indian CROs, and it predates the September 2019 notification. Its reasoning should not be applied without considering the later notification and the current contract.
What zero-rated treatment means for pricing
Section 16 treats qualifying exports of services as zero-rated supplies. Zero-rated does not mean the same thing as an exempt domestic supply, nor does it mean that GST-related costs and cash-flow effects disappear. Subject to the Act and rules, a registered supplier may make a zero-rated supply without payment of IGST under a bond or letter of undertaking (LUT) and claim a refund of eligible unutilised input tax credit. Eligibility, documentation and timing remain relevant.
For a CRO, this means modelling eligible input tax credit and refund timing alongside the service fee. Do not assume a refund will be immediate or build an unsupported market-wide “GST premium” into the quote.
Choose a quote structure that matches the tax conclusion
After reviewing the scope, parties, place of supply and export conditions, make the quote’s tax treatment explicit. These are commercial structures, not separate statutory categories:
| Quote approach | When it fits | What to state |
|---|---|---|
| Zero-rated export treatment | Only after the CRO has assessed the export conditions, including place of supply, and confirmed that the transaction qualifies. | Identify the intended zero-rated treatment and specify the applicable compliance route and supporting-document responsibilities. Check current bond/LUT and refund requirements. |
| Fee exclusive of applicable GST | Useful where the final tax treatment requires confirmation or the supply may be taxable. | State that applicable GST will be charged if the supply is determined to be taxable, and set out how a reasoned tax review or change in treatment affects invoicing. |
| Fee inclusive of GST | Use only when the parties deliberately agree who bears the tax cost and the likely treatment has been assessed. | Define what “inclusive” covers and how the parties will handle a later change in tax determination. Do not imply a universal rate or export outcome. |
Whatever structure the CRO chooses, keep tax language consistent with the scope and the actual contracting and invoicing entities. Separate professional fees from expressly identified pass-through or reimbursable items for clarity, but do not assume that reimbursement is outside the taxable value; assess the treatment of each item.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Do not apply one GST rate to every CRO contract
CBIC’s rate table lists 18% for “other services” under heading 9989. That entry alone does not establish that every clinical-trial service, or every CRO service bundle, belongs under that heading or bears that rate. If the supply is taxable, determine the applicable classification and rate for the actual services and any bundled components using the current rate notification. A taxable supply and a qualifying zero-rated export are different treatments; do not use a general rate-table entry as a substitute for deciding which applies.
Contract and pricing checks before the quote is final
- Record the customer’s legal name, country and address, and identify the supplier, contracting party, recipient and invoicing entity.
- Align the statement of work with the actual trial activities, deliverables, sites and parties. Describe distinct service components instead of relying on a broad label where the contract contains a bundle.
- Document the payment currency and route, and retain evidence relevant to the recipient and receipt of consideration.
- Specify whether the fee is exclusive or inclusive of applicable GST, who is responsible for the relevant documentation, and how a tax change will be handled.
- Assess pass-through and reimbursable items individually rather than presuming they are excluded from taxable value.
- Model eligible input tax credit and potential refund timing as working-capital considerations.
The applicable framework is India’s GST law as of 7 October 2026. The legal framework alone does not determine the treatment of a particular CRO contract: obtain contract-specific Indian GST advice before finalising a tax clause or claiming zero-rating.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
